Recap: Blueprint Medicines Q3 Earnings

Recap: Blueprint Medicines Q3 Earnings

Blueprint Medicines BPMC reported its Q3 earnings results on Tuesday, November 1, 2022 at 08:00 AM.

Here's what investors need to know about the announcement.


Blueprint Medicines beat estimated earnings by 10.44%, reporting an EPS of $-2.23 versus an estimate of $-2.49.

Revenue was up $41.79 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.45 which was followed by a 6.06% increase in the share price the next day.

Here's a look at Blueprint Medicines's past performance:


Quarter Q2 2022 Q1 2022 Q4 2021 Q3 2021
EPS Estimate -2.23 -1.94 -1.65 -1.63
EPS Actual -2.68 -1.79 -0.99 -2
Revenue Estimate 37.24M 36.65M 102.69M 42.47M
Revenue Actual 36.55M 62.73M 107.02M 24.19M

To track all earnings releases for Blueprint Medicines visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: BZI-RecapsEarnings